Adial Pharmaceuticals Stock (NASDAQ: ADIL)

Adial Pharmaceuticals (NASDAQ:ADIL) Stock, Quote.Headers.trade-ideas

Adial Pharmaceuticals

Adial Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company develops prescription medications for addiction and related disorders. Its lead product is AD04, which is for the treatment of alcohol use disorder. The active ingredient in AD04 is ondansetron, a serotonin-3 antagonist.

ADIL

Biotech

News

Health Care

Market-Moving Exclusives

Exclusives

General

Adial Pharmaceuticals expands its IP with a U.S. patent for targeted AUD treatment using AD04, supporting its personalized medicine strategy.

EXCLUSIVE: Adial Pharmaceuticals&#39; Lead Drug Secures Key US Patent For  Alcohol Dependence Based on Expanded Genotype Combinations

Adial Pharmaceuticals completes PK study for AD04 in AUD, meeting FDA requirements and preparing for Phase 3 trial. Data supports 505(b)(2) application.

EXCLUSIVE: Adial Pharmaceuticals Reveals Topline Results From Pharmacokinetics Study Of AD04 For Alcohol Use Disorder

Analysts

Initiation

Pre-Market Outlook

Analyst Ratings

Trading Ideas

ACHV

RMTI

This Turning Point Brands Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

Adial Pharmaceuticals, Inc - Common Stock

Adial Pharmaceuticals Inc

RBC Capital analyst Jonathan Atkin maintains Charter Communications (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) with a Sector Perform and lowers the price target from $390 to $380.

Price Target

CHTR

RBC Capital Maintains Sector Perform on Charter Communications, Lowers Price Target to $380

JP Morgan analyst Jeremy Metz maintains First Quantum Minerals (TSX:<a class="ticker" href="https://www.benzinga.com/stock/FM#TSX">FM</a>) with a Neutral and raises the price target from C$17 to C$18.

TSX:FM

JP Morgan Maintains Neutral on First Quantum Minerals, Raises Price Target to C$18

RBC Capital analyst Drew McReynolds reiterates Cogeco Communications (TSX:<a class="ticker" href="https://www.benzinga.com/stock/CCA#TSX">CCA</a>) with a Sector Perform and maintains C$77 price target.

Reiteration

TSX:CCA

RBC Capital Reiterates Sector Perform on Cogeco Communications, Maintains C$77 Price Target

Grab Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) shares are trading marginally higher <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">in the premarket session on Wednesday.</a>
The firm has announced a <a target="_blank" href="https://www.grab.com/sg/press/others/grab-and-byd-enter-strategic-partnership-to-expand-electric-vehicle-fleet-offering-across-southeast-asia/" rel="noreferrer noopener">regional partnership</a> with BYD to expand access to up to 50,000 electric vehicles for Grab&#8217;s driver-partners across Southeast Asia, enhancing the availability of green vehicles for its users.
This collaboration aims to overcome the region&#8217;s key barrier to EV adoption: high upfront costs.
This partnership spans six Southeast Asian countries—Indonesia, Malaysia, Philippines, Singapore, Thailand, and Vietnam—and includes models like the DENZA D9, BYD ATTO3, BYD SEAL, and BYD M6.
The DENZA D9, a luxury electric vehicle, will be featured in GrabExec, setting a new standard for executive transportation with its advanced features and sustainability.
Last July, BYD announced a multi-year strategic partnership to add 100,000 new BYD electric vehicles to the&nbsp;Uber platform <a target="_blank" href="https://www.benzinga.com/markets/equities/24/07/40077563/uber-and-byd-team-up-for-electric-future-100k-evs-to-hit-the-road" rel="noreferrer noopener">in key global markets.</a> However, the deal with Uber focused on Europe and Latin America, with plans to expand to the Middle East, Canada, Australia, and New Zealand.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/01/42996752/us-stocks-to-open-higher-ahead-of-december-inflation-data-all-eyes-on-baking-earnings-by-jpm-goldman-citi-wells-fargo" rel="noreferrer noopener">US Stocks To Open Higher Ahead Of December Inflation Data: All Eyes On Banking Stocks As JPMorgan, Goldman, Citi, Wells Fargo Report Quarterly Earnings</a>
In the latest development with Grab, BYD plans to provide Grab&#8217;s fleet and driver-partners with access to affordable BYD vehicles, including extended warranties for the vehicles&#8217; batteries.
Drivers can choose to rent these EVs through Grab&#8217;s fleet partners or access financing options via Grab&#8217;s car ownership schemes. This partnership aligns with Grab&#8217;s sustainability goals, helping accelerate the transition to zero-emission transportation.
In countries like Singapore and Thailand, Grab users can select an &#8220;Eco-Friendly Ride&#8221; option at no extra charge, prioritizing green vehicles for their rides.
Liu Xueliang, General Manager of BYD Asia Pacific Auto Sales Division, said, &#8220;We are excited to partner with Grab as the leading on-demand transport provider in Southeast Asia and push forward the transition to electric vehicles in the region.&#8221;
Per a <a target="_blank" href="https://www.statista.com/outlook/mmo/electric-vehicles/southeast-asia" rel="noreferrer noopener">report</a> by Statista, the Electric Vehicles market in Southeast Asia is expected to reach $6.798 billion by 2025. From 2025 to 2029, the market is projected to grow at a rate of 4.02% annually. By 2029, the market volume is expected to hit $7.958 billion.
The partnership will also focus on deep technological integration to enhance Grab&#8217;s services. BYD vehicles will integrate with Grab&#8217;s platform through IoT, providing real-time data on driving patterns and behaviors. This data will help improve driver safety and overall experience, with features like larger screens displaying jobs, navigation, and chats directly in the vehicle&#8217;s head unit.
The integration of real-time data, such as weather and traffic conditions, will also help improve ride reliability and route optimization, ensuring better ETA accuracy and efficient navigation.
Price Action: GRAB shares are trading higher by 2.06% to $4.45 premarket at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/01/42967576/meta-investors-push-mark-zuckerberg-to-replace-72b-cash-with-bitcoin-to-combat-inflation-heres-what-it-means-for-investors" target="_blank" rel="noreferrer noopener">Meta Investors Push Mark Zuckerberg To Replace $72B Cash With Bitcoin To Combat Inflation: Here&#8217;s What It Means For Investors</a></li>
</ul>
Photo via Shutterstock.

Equities

Markets

Movers

BYDDY

GRAB

Grab Teams Up With BYD To Boost EV Availability For Southeast Asia's Driver-Partners

- Presentation&nbsp;
&nbsp;
<figure class="image"><img src="https://www.sec.gov/Archives/edgar/data/1803901/000095017025005641/talk-ex99_1s19.jpg" alt="Slide 19" /></figure>

Guidance

TALK

Talkspace Sees 2024 Revenue Guidance Of ~$185M-$195M, Up 23%-30% YoY; 3-Year Revenue CAGR Outlook Of 20%-25%

VCIG

VCI Global Announces Exclusive Distributorship Of Secure Encryption Storage Limited For Data Security Solutions In Malaysia

WIIM

CVGW

Calavo Growers shares are trading lower after the company reported worse-than-expected Q4 adjusted EPS results.

PRTH

Priority Technology shares are trading lower after the company announced a share offering of 9,157,600 shares.

CEO Marc Rowan to Enter Into 5-Year Employment Agreement Extension
Jim Zelter Named President of Apollo Global Management
John Zito Named Co-President of Apollo Asset Management Alongside Scott Kleinman
NEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Apollo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APO#NYSE">APO</a>) today announced that Jim Zelter has been named President of Apollo Global Management, Inc. (AGM), the holding company for its asset management and retirement services businesses. The newly created role reflects Apollo's continued operational expansion and its significant growth plans across both the Apollo Asset Management, Inc. (AAM) and Athene Holding Ltd. subsidiaries. As President, Zelter will work closely with AGM CEO Marc Rowan to drive Apollo's recently announced five-year plan and lead a number of key strategic initiatives across its asset management and retirement services businesses.

Management

Apollo Announces Jim Zelter As President Of Apollo Global Management; John Zito Named Co-President Of Apollo Asset Management With Scott Kleinman; CEO Marc Rowan Signs 5-Year Agreement Extension

TOMZ

TOMI Environmental Solutions Regains Compliance With Nasdaq Requirements

GNLN

Greenlane Regains Full Compliance With Nasdaq Continued Listing Rules
ACCESSWIRE

KROS

Keros Therapeutics shares are trading lower after the company announced an update on its Phase 2 TROPOS trial and halted all dosing based on the ongoing safety review.

JP Morgan analyst Tami Zakaria maintains Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) with a Neutral and raises the price target from $450 to $470.

JP Morgan Maintains Neutral on Deere, Raises Price Target to $470

QUBT

Quantum Computing Collaborates With Sanders Tri-Institutional Therapeutics Discovery Institute To Support Research Using Dirac-3 Systems

BECN

QXO Proposes To Acquire Beacon Roofing Supply For $124.25/Share In Cash, Implying Total Transaction Valued Of ~$11B

Tempus AI, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEM#NASDAQ">TEM</a>), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of the company's FDA-approved, NGS-based in vitro diagnostic device, xT CDx. Beginning today, xT CDx is now available for all ordering clinicians nationwide. xT CDx is a FDA-approved test that delivers comprehensive insights with one of the largest reported gene panels available.
xT CDx is a 648-gene next-generation sequencing test for solid tumor profiling, which includes microsatellite instability status and companion diagnostic claims for colorectal cancer patients. xT CDx leverages a normal-matched approach, which is a method of parallel DNA sequencing of a solid tumor and normal patient sample that can lead to more accurate identification of cancer-driving somatic variants. All orders for tumor + normal match tests – traditionally run on the company's signature xT assay – will now be run as xT CDx with no changes to the current ordering workflow.

Tempus Announces The Launch Of FDA-Approved xT CDx Test, Now Available For All Ordering Clinicians Nationwide

MYGN

Myriad Genetics Sees FY25 Adj. EPS $0.07-$0.11 Vs $0.08 Est.; Revenue $840M-$860M Vs $876.702M Est.

TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TCBP#NASDAQ">TCBP</a>)&nbsp;a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced that it intends to begin Proof of Concept preclinical studies for its lead therapeutic TCB008, for treatment in H5N1, commonly known as "Bird Flu." The Company is currently approaching potential university partners to expedite the preclinical work required for a Phase I study.
H5N1 is a viral infection often contracted by contact with sick birds, yet it can also be passed from person to person. Symptoms begin within two to eight days and can seem like the common flu, causing cough, fever, sore throat, muscle aches, headache, and shortness of breath. The disease can carry a high mortality in humans. Some antiviral drugs, if taken within two days of symptoms, may help. Last week, the <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4340843-1&amp;h=149896997&amp;u=https%3A%2F%2Fldh.la.gov%2Fnews%2FH5N1-death&amp;a=Louisiana+Department+of+Health+recently+reported+the+first+U.S.+death+from+H5N1">Louisiana Department of Health recently reported the first U.S. death from H5N1</a>.

TCBP

TCBP Announces That It Intends To Begin Proof Of Concept Preclinical Studies For Its Lead Therapeutic TCB008, For Treatment In H5N1, Commonly Known As "Bird Flu"

Myriad Genetics Sees Prelim. Q4 Adj. EPS $0.03-$0.04 Vs $0.03 Est.; Revenue $209M-$211M Vs $212.873M Est.

JP Morgan analyst Tami Zakaria maintains CNH Industrial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNH#NYSE">CNH</a>) with a Neutral and raises the price target from $12 to $13.

JP Morgan Maintains Neutral on CNH Industrial, Raises Price Target to $13

Adial Pharmaceuticals reports Q3 results

Rodman & Renshaw initiated coverage of Adial Pharmaceuticals (ADIL) with a Buy rating and $8 price target The firm believes Adial has the potential...

Adial Pharmaceuticals initiated with a Buy at Rodman & Renshaw

Adial Pharmaceuticals (ADIL) announced that it has completed a pharmacokinetics, PK, study of AD04, the Company's lead investigational genetically ...

Adial Pharmaceuticals announces topline results from AD04-103 PK study

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Hold rating on Adial Pharmaceuticals (ADIL – Research Report). The com...

Maxim Group Sticks to Their Hold Rating for Adial Pharmaceuticals (ADIL)

Adial Pharmaceuticals ( ($ADIL) ) just unveiled an announcement. Adial Pharmaceuticals has completed a significant pharmacokinetics study for its l...

Adial Pharmaceuticals Advances AD04 with Promising Study Results

Adial Pharmaceuticals (ADIL) announced patent number 12150931 was issued on November 26, 2024 by the United States Patent and Trademark Office, exp...

Adial granted U.S. patent for treatment of alcohol, drug dependence

Adial Pharmaceuticals ( ($ADIL) ) has shared an announcement. Adial Pharmaceuticals has extended its CEO Cary Claiborne's tenure with a new three-y...

Adial Pharmaceuticals Extends CEO Cary Claiborne's Tenure

An update from Adial Pharmaceuticals ( ($ADIL) ) is now available. Adial Pharmaceuticals has entered into a new Purchase Agreement with Alumni Capi...

Adial Pharmaceuticals' New Purchase Agreement with Alumni Capital

16:15 EST Adial Pharmaceuticals (ADIL) files to sell 5.0M shares of common stock for holders Published first on TheFly – the ultimate source for re...

Adial Pharmaceuticals files to sell 5.0M shares of common stock for holders

Adial Pharmaceuticals ( ($ADIL) ) has provided an announcement. Adial Pharmaceuticals has updated its corporate presentation, highlighting the deve...

Adial Pharmaceuticals Highlights AD04 for Alcohol Use Disorder

Earnings

Press Releases

Adial Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

Adial Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Adial Pharmaceuticals Announces Database Lock in Pharmacokinetics Study of AD04 for the Treatment of Alcohol Use Disorder

Adial Pharmaceuticals Commends the National Institute on Alcohol Abuse and Alcoholism's New Definition of Recovery

Legal

Adial Pharmaceuticals Receives Notice of Allowance for U.S. Patent Covering Expanded Genotype Combinations Identified Using the Company's Genetic Diagnostic for Addiction Treatment

Comments

Adial Pharmaceuticals

Adial Pharmaceuticals (ADIL) Forecast

Adial Pharmaceuticals (NASDAQ:ADIL) Stock, Quote.Headers.trade-ideas

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga